The global demand for metabolic and weight-management therapeutics has created unprecedented production bottlenecks, forcing pharmaceutical leaders to reallocate capital toward contract development and manufacturing organizations (CDMOs).
Fill-Finish Capacity Constraints
The primary limiting factor in the supply chain remains sterile fill-finish capacity for auto-injector devices. Establishing new greenfield manufacturing facilities requires a multi-year lead time, driving immediate reliance on third-party specialized processors.
Long-Term Capital Commitment
Major drugmakers are issuing multi-year take-or-pay contracts to secure dedicated CDMO capacity. This capital commitment signals that supply constraints are expected to persist as expanded clinical indications for the drug class receive regulatory approval.